Peter W. Steelman
Algemeen Directeur bij Avadel Pediatrics, Inc.
Profiel
Peter Steelman is Partner on the Therapeutics group at Deerfield and joined the Firm in 2013.
Mr. Steelman was a co-founder of FSC Laboratories, Inc., a pediatric-focused specialty pharmaceutical company acquired by Deerfield in 2013, where Mr. Steelman had been President and CEO from 2004 through its sale in 2016.
Prior to FSC, he spent 12 years in healthcare corporate and investment banking at Wachovia Capital Markets, Bank of Montreal and Citicorp.
Before receiving his M.B.A.
from Columbia Business School, Mr. Steelman was an equity research associate at Kidder, Peabody & Co. covering commercial banks.
Mr. Steelman received his B.A.
from DePauw University.
Actieve functies van Peter W. Steelman
| Bedrijven | Functie | Begin |
|---|---|---|
Avadel Pediatrics, Inc.
 Avadel Pediatrics, Inc. Pharmaceuticals: MajorHealth Technology Avadel Pediatrics, Inc. markets and distributes pediatric pharmaceutical products and medical devices. It offers AcipHex Sprinkle, Cefaclor for Oral Suspension, Flexichamber and Karbinal ER products. The company was founded by Peter W. Steelman in 2004 and is headquartered in Charlotte, NC. | Algemeen Directeur | 01-01-2004 |
Stelexis Therapeutics LLC
 Stelexis Therapeutics LLC Pharmaceuticals: MajorHealth Technology Stelexis Therapeutics LLC focuses on identifying and isolating the earliest definable stem and progenitor cells, which harbor clonal properties and pre-cancerous alterations. The company was founded by Ulrich Steidl, Derrick Rossi, Amit Verma, Evripidis Gavathiotis, and Roman Perez-Soler in 2017 and is headquartered in New York ,NY. | Directeur/Bestuurslid | - |
Deerfield Management Co. LP (Private Equity)
 Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York. | Private Equity Investor | 01-04-2013 |
Cystetic Medicines, Inc.
 Cystetic Medicines, Inc. Pharmaceuticals: MajorHealth Technology Cystetic Medicines, Inc. is a clinical-stage biotechnology company located in Champaign, IL. The company is pioneering the development of small molecule anion channel prosthetics to restore protein function in people with cystic fibrosis (CF). The company utilizes a proprietary inhaled dry powder formulation that enables improved dose consistency and high efficiency delivery to the airways. Currently, they are focused on the development of CM001, a novel inhalable small molecule therapeutic designed to restore ion balance and host defenses in the lungs to treat CF. The company was founded in 2020 based on the work of Dr. Martin Burke of the University of Illinois at Urbana-Champaign and Dr. Michael Welsh at the University of Iowa. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Peter W. Steelman
| Bedrijven | Functie | Einde |
|---|---|---|
FSC Laboratories, Inc.
 FSC Laboratories, Inc. Drugstore ChainsRetail Trade FSC Laboratories, Inc. engages in development of prescription medicines and medical devices. The company was founded by Peter W. Steelman in April 16, 2004 and is headquartered in Charlotte, NC. | Algemeen Directeur | 01-02-2016 |
Wachovia Securities LLC
 Wachovia Securities LLC Investment Banks/BrokersFinance Wachovia Securities LLC offered equity, fixed income, and structured products. It was founded in 2001 and was headquartered in St. Louis, MO. | Private Equity Investor | 01-03-2004 |
Opleiding van Peter W. Steelman
| DePauw University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Wachovia Securities LLC
Wachovia Securities LLC Investment Banks/BrokersFinance Wachovia Securities LLC offered equity, fixed income, and structured products. It was founded in 2001 and was headquartered in St. Louis, MO. | Finance |
Deerfield Management Co. LP (Private Equity)
Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York. | Finance |
FSC Laboratories, Inc.
FSC Laboratories, Inc. Drugstore ChainsRetail Trade FSC Laboratories, Inc. engages in development of prescription medicines and medical devices. The company was founded by Peter W. Steelman in April 16, 2004 and is headquartered in Charlotte, NC. | Retail Trade |
Avadel Pediatrics, Inc.
Avadel Pediatrics, Inc. Pharmaceuticals: MajorHealth Technology Avadel Pediatrics, Inc. markets and distributes pediatric pharmaceutical products and medical devices. It offers AcipHex Sprinkle, Cefaclor for Oral Suspension, Flexichamber and Karbinal ER products. The company was founded by Peter W. Steelman in 2004 and is headquartered in Charlotte, NC. | Health Technology |
Stelexis Therapeutics LLC
Stelexis Therapeutics LLC Pharmaceuticals: MajorHealth Technology Stelexis Therapeutics LLC focuses on identifying and isolating the earliest definable stem and progenitor cells, which harbor clonal properties and pre-cancerous alterations. The company was founded by Ulrich Steidl, Derrick Rossi, Amit Verma, Evripidis Gavathiotis, and Roman Perez-Soler in 2017 and is headquartered in New York ,NY. | Health Technology |
Cystetic Medicines, Inc.
Cystetic Medicines, Inc. Pharmaceuticals: MajorHealth Technology Cystetic Medicines, Inc. is a clinical-stage biotechnology company located in Champaign, IL. The company is pioneering the development of small molecule anion channel prosthetics to restore protein function in people with cystic fibrosis (CF). The company utilizes a proprietary inhaled dry powder formulation that enables improved dose consistency and high efficiency delivery to the airways. Currently, they are focused on the development of CM001, a novel inhalable small molecule therapeutic designed to restore ion balance and host defenses in the lungs to treat CF. The company was founded in 2020 based on the work of Dr. Martin Burke of the University of Illinois at Urbana-Champaign and Dr. Michael Welsh at the University of Iowa. | Health Technology |
